Literature DB >> 12161596

PTPN11 mutations in LEOPARD syndrome.

E Legius1, C Schrander-Stumpel, E Schollen, C Pulles-Heintzberger, M Gewillig, J-P Fryns.   

Abstract

LEOPARD syndrome is an autosomal dominant disorder with multiple lentigines, congenital cardiac abnormalities, ocular hypertelorism, and retardation of growth. Deafness and genital abnormalities are less frequently found. We report a father and daughter and a third, unrelated patient with LEOPARD syndrome. Recently, missense mutations in the PTPN11 gene located in 12q24 were found to cause Noonan syndrome. All three cases of LEOPARD syndrome reported here have a Y279C mutation in the PTPN11 gene. We hypothesise that some PTPN11 mutations are associated with the typical Noonan syndrome phenotype and that other mutations, such as the Y279C mutation reported here, are associated with both the Noonan syndrome phenotype and with skin pigmentation anomalies, such as multiple lentigines or café au lait spots.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161596      PMCID: PMC1735195          DOI: 10.1136/jmg.39.8.571

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  79 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.

Authors:  Sarah A Clay; Timothy L Domeier; Laurin M Hanft; Kerry S McDonald; Maike Krenz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

3.  SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.

Authors:  Yvette Langdon; Panna Tandon; Erika Paden; Jennifer Duddy; Joan M Taylor; Frank L Conlon
Journal:  Development       Date:  2012-01-25       Impact factor: 6.868

Review 4.  The neural crest in cardiac congenital anomalies.

Authors:  Anna Keyte; Mary Redmond Hutson
Journal:  Differentiation       Date:  2012-05-15       Impact factor: 3.880

5.  Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11.

Authors:  Kamini Kalidas; Adam C Shaw; Andrew H Crosby; Ruth Newbury-Ecob; Lynn Greenhalgh; Isabel K Temple; Caroline Law; Amisha Patel; Michael A Patton; Steve Jeffery
Journal:  J Hum Genet       Date:  2004-12-10       Impact factor: 3.172

6.  SHP-2 tyrosine phosphatase in human diseases.

Authors:  Hong Zheng; Shawn Alter; Cheng-Kui Qu
Journal:  Int J Clin Exp Med       Date:  2009-01-30

7.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

8.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

9.  Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.

Authors:  Hong Zheng; Wen-Mei Yu; Ronald R Waclaw; Maria I Kontaridis; Benjamin G Neel; Cheng-Kui Qu
Journal:  Sci Signal       Date:  2018-03-20       Impact factor: 8.192

10.  Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Authors:  Zhi-Hong Yu; Jie Xu; Chad D Walls; Lan Chen; Sheng Zhang; Ruoyu Zhang; Li Wu; Lina Wang; Sijiu Liu; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2013-03-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.